In today’s briefing:
- Anixa Biosciences’ Innovative Approach to Help T- Cells Address Solid Tumors
- Novavax in Crisis Mode: Sales Crumble & Investor Revolt Grows!
- Smith & Nephew: An Insight Into Its Manufacturing Capacity Adjustments
Anixa Biosciences’ Innovative Approach to Help T- Cells Address Solid Tumors
- Anixa is a biotech company with two early-stage clinical developments: (1) a novel type of chimeric antigen receptor (CAR)-T-cell therapy for the treatment of terminally ill ovarian cancer patients; (2) and a breast cancer vaccine designed as both a treatment and prophylactic.
- The vaccine is being used to train patients’ T-cells to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer.
- Additionally, Anixa runs several pre-clinical programs.
Novavax in Crisis Mode: Sales Crumble & Investor Revolt Grows!
- Novavax, once a prominent pandemic-era vaccine contender, is now in the midst of intensifying turmoil.
- The latest blow comes from Shah Capital, the company’s largest shareholder, which is calling for an outright sale of the biotech firm.
- This move follows a string of financial disappointments, declining market relevance, and concerns about Novavax’s execution under current leadership.
Smith & Nephew: An Insight Into Its Manufacturing Capacity Adjustments
- Smith & Nephew’s recent earnings announcement for the second quarter and the first half of the year indicates a strategic trajectory that is both complex and multifaceted.
- On the whole, the underlying growth figures are a positive highlight, with the company reporting a 6.7% increase in revenue.
- This growth is seen across all regions and business units, showing robust momentum especially in Sports Medicine, Wound Management, and Orthopaedics.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
